Interdisciplinary protocol of Cystic Fibrosis
DOI:
https://doi.org/10.34019/1982-8047.2024.v50.45566Keywords:
Cystic Fibrosis, Clinical Protocols, User Embracement, Interdisciplinary PlacementAbstract
Introduction: Cystic Fibrosis (CF), known as the “salty kiss disease” or “Mucoviscidosis,” is the most common and lethal genetic disease in childhood. Implementing treatment protocols for this disease is crucial to ensure standardized and high-quality care, integrating various specialties, improving clinical management, and promoting increased survival. This action was fundamental for the CF Reference Center at the University Hospital of the Federal University of Juiz de Fora, recognized by the Ministry of Health as a Reference Service for Rare Diseases. Objective: To raise awareness about CF and present the work protocol implemented by the team upon becoming a reference in rare diseases. Methods: Development of a protocol for interdisciplinary care for people with CF, created through team meetings at the Reference Center in 2022 and 2023, to discuss the main guidelines from the current literature, consolidated into a single document. The protocol was designed to accommodate patients of all ages, from diagnosis to the most complex clinical conditions. Results: The protocol was subdivided into an introduction, history, the disease, involved specialties, access to care, and systematization of comprehensive and interdisciplinary clinical approach. Conclusion: The construction and implementation of the protocol represent a significant advance in the overall approach to CF in our environment, establishing evidence-based guidelines for integrated disease management and care. By standardizing care, the protocol minimizes variations in clinical practice, ensuring consistent and effective care based on national and international literature.
Downloads
References
Januário JN. Triagem neonatal em Minas Gerais: análise do contexto histórico e político-institucional com enfoque nas estratégias empregadas e resultados alcançados [tese de doutorado]. Belo Horizonte: Universidade Federal de Minas Gerais; 2015.
Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde (CONITEC). Protocolos Clínicos e Diretrizes Terapêuticas. Fibrose cística [Internet]. Brasília: Ministério da Saúde; 2024 [citado em 2024 out. 13]. Disponível em: https://www.gov.br/conitec/pt-br/midias/protocolos/resumidos/pcdt-resumido-fibrose-cistica.pdf.
Secretaria de Estado de Saúde de Minas Gerais. Resolução SES nº 1088 de 29 de dezembro de 2006. Institui a rede estadual de atenção à saúde do portador de fibrose cística [Internet]. Belo Horizonte; 2006 [citado em 2024 jul. 24]. Disponível em: https://www.saude.mg.gov.br/index.php?option=com_gmg&controller=document&id=743-resolucao-ses-n%C2%BA-1088-de-29-de-dezembro-de-2006-sesmg?layout=print.
Brasil. Ministério da Saúde. Portaria GM/MS nº 1.890, de 10 de agosto de 2021. Habilita o Hospital Universitário da UFJF como serviço de referência em doenças raras e estabelece recurso do bloco de manutenção das ações e serviços públicos de saúde - Grupo de Atenção Especializada, a ser disponibilizado por meio do Fundo de Ações Estratégicas e Compensação - FAEC ao estado de Minas Gerais e município de Juiz de Fora [Internet]. Brasília: Ministério da Saúde; 2021 [citado em 2024 out. 13]. Disponível em: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2021/prt1890_11_08_2021.html.
Duarte MC, Vergara AA. Fibrose Cística. In: Moraes-Filho, JPP. Tratado das enfermidades gastrintestinais e pancreáticas. 1ª ed. São Paulo: Editora Roca; 2008.
Athanazio RA, Filho LVRFS, Vergara AA, Ribeiro AF, Riedi CA, Procianoy EFA, et al. Diretrizes brasileiras de diagnóstico e tratamento da fibrose cística. J Bras Pneumol. 2017; 43(3):219-45. doi: 10.1590/S1806-37562017000000065.
Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017; 181S:S4-S15.e1. doi: 10.1016/j.jpeds.2016.09.064.
Gursoy TR, Asfuroglu P, Eyuboglu TS, Aslan AT, Yilmaz AI, Unal G, et al. Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers. Eur J Pediatr. 2023; 182(3):1067-76. doi: 10.1007/s00431-022-04766-4.
Wilschanski M, Munck A, Carrion E, Cipolli M, Collins S, Colombo C, et al. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clinical Nutrition. 2024; 43(2):413-445. doi: 10.1016/j.clnu.2023.12.017.
Aidoo E, Alexander S, Alshafi K, Al-Yaghchi C, Anderson AK, Balfour-Lynn I, et al. Clinical guidelines: care of children with cystic fibrosis [Internet]. Royal Brompton Hospital. 9th ed. Sydney; 2023 [citado em 2024 jul. 28]. Disponível em: https://www.rbht.nhs.uk/sites/default/files/Cystic%20fibrosis%20guidelines/CF%20G%202023/CF%20guideline%202023%20FINAL_081223.pdf.
Davis SD, Rosenfeld M, Chmiel J. Cystic fibrosis a multi-organ system approach. 1th ed. Totowa: Humana Press; 2020.
Scott J, Jones AM, Hanley KP, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis [Internet]. Aliment Pharmacol Ther. 2022; 55(4):389-400. doi: 10.1111/apt.16749.
Associação Brasileira de Fisioterapia Cardiorrespiratória e Fisioterapia em Terapia Intensiva (ASSOBRAFIR). Recomendação brasileira de fisioterapia na fibrose cística: um guia das boas práticas clínicas [Internet]. São Paulo: ASSOBRAFIR Ciência; 2019 [citado em 2024 jul. 30]. Disponível em: http://portalgbefc.org.br/ckfinder/userfiles/files/Recomenda%C3%A7%C3%A3o%20Brasileira%20de%20Fisioterapia%20na%20Fibrose%20C%C3%ADstica.pdf.
Moreno RMG, García-Clemente M, Diab-Cáceres L, Martínez-Vergara A, Martínez-García MA, Gómez-Punter RM. Treatment of pulmonary disease of cystic fibrosis: a comprehensive review. Antibiotics. 2021; 10(5):486. doi: 10.3390/antibiotics10050486.
Kapnadak SG, Dimango E, Hadjiliadis D, Hempstead SE, Tallarico E, Pilewski JM. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. Journal of Cystic Fibrosis. 2020; 19(3):344-54. doi: 10.1016/j.jcf.2020.02.015.
Chilvers MA, Cho E, Dagenais R, Daigneault P, Lavoie A, McKinney M, et al. Canadian clinical consensus guideline for initiation, monitoring and discontinuation of CFTR modulator therapies for patients with cystic fibrosis [Internet]. Cystic Fibrosis Canada’s Healthcare Advisory Council; 2022 [citado em 2024 jul. 31]. Disponível em: https://www.cysticfibrosis.ca/uploads/Consensus%20Guideline%20-%20CFTR%20Modulators%20June%202022%20(004)%20FINAL-ua.pdf.
Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18):1663-72. doi: 10.1056/NEJMoa1105185.
Tewkesbury DH, Robey RC, Barry PJ. Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy. Breathe. 2021; 17(4):210112. doi: 10.1183/20734735.0112-2021.
Grupo Brasileiro de Estudo de Fibrose Cística. Relatório do Registro Brasileiro de Fibrose Cística 2021 [Internet]. 2021 [citado em 2024 ago. 3]. Disponível em: http://www.gbefc.org.br/ckfinder/userfiles/files/Rebrafc_2021_REV_fev24.pdf.
Cystic Fibrosis Foundation. Patient registry annual data report 2021 [Internet]. Bethesda (Maryland); 2021 [citado em 2024 ago. 3]. Disponível em: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf.
Garcia B, Flume PA. Pulmonary complications of cystic bibrosis. Semin Respir Crit Care Med. 2019; 40(6):804-9. doi: 10.1055/s-0039-1697639.
Burton SJ, Hachem C, Abraham JM. Luminal gastrointestinal manifestations of cystic fibrosis. Curr Gastroenterol Rep. 2021; 23(3):4. doi: 10.1007/s11894-021-00806-5.
Ley D, Turck D. Digestive outcomes in cystic fibrosis. Best Practice & Research Clinical Gastroenterology. 2022; 56-57:101788. doi: 10.1016/j.bpg.2022.101788.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Marta Cristina Duarte, Lucélia Paula Cabral Schmidt, Célio de Barros Barbosa, José Antonio Chehuen Neto, Luciana Santos de Carvalho, Mário Flávio Cardoso de Lima, Raphaela Receputi da Silva , Sarah Moreira de Sousa Gomes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Cessão de Primeira Publicação à HU Revista
Os autores mantém todos os direitos autorais sobre a publicação, sem restrições, e concedem à HU Revista o direito de primeira publicação, com o trabalho licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento irrestrito do trabalho, com reconhecimento da autoria e crédito pela citação de publicação inicial nesta revista, referenciando inclusive seu DOI.
